Neisseria meningitidis B vaccines

Expert Review of Vaccines

Volumn 10, Issue 9, 2011, Pages 1337-1351

  Panatto, Donatella ^a   Amicizia, Daniela ^a   Lai, Piero Luigi ^a   Gasparini, Roberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

meningococcal B vaccines; meningococcus B; Neisseria meningitides; prevention of meningococcal disease; vaccination

Indexed keywords

BINDING PROTEIN; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; NEISSERIA MENINGITIDIS B VACCINE; OUTER MEMBRANE VESICLE VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; BACTERICIDAL ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MEMBRANE VESICLE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; VACCINATION;

ADOLESCENT; ANTIGENS, BACTERIAL; CHILD; CHILD, PRESCHOOL; EUROPE; GENOME, BACTERIAL; HUMANS; IMMUNE EVASION; INCIDENCE; INFANT; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; NEW ZEALAND; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UNITED STATES; VACCINATION; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 80053025090     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.103     Document Type: Review

References (126)

1. Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. J. Travel. Med. 17(Suppl. 3-8) (2010).
2. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin. Infect. Dis. 50(Suppl. 2), S37-S44 (2010).
3. Hill DJ, Griffiths NJ, Borodina E, Virji M. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin. Sci. (Lond.) 118(9), 547-564 (2010).
4. Branham SE. Serological relationships among meningococci. Bact. Rev. 17, 175-188 (1953).
5. Vedros NA. Development of meningococcal serogroups. In: Evolution of Meningococcal Disease. Vedros NA (Ed.). CRC Press, Roca Raton, FL, USA, 33-37 (1987).
6. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Vaccines, 5th ed. Plokin SA, Orestein WA (Eds). WB Saunders Co, Philadelphia, PA, USA (2008).
7. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369, 2196-2210 (2007). (Pubitemid 46977462)
8. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 27(Suppl. 2), B51-B63 (2009).
9. Wilder-Smith A. Meningococcal vaccine in travelers. Curr. Opin. Infect. Dis. 20(5), 454-460 (2007). (Pubitemid 47359640)
10. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369, 2196-2210 (2007). (Pubitemid 46977462)
11. van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin. Microbiol. Rev.13, 144-166 (2000). (Pubitemid 30039347)
12. Rosenstein NE, Perkins BA, Stephens DS et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J. Infect. Dis. 180(6), 1894-1901 (1999).
13. Cohn AC, MacNeil JR, Harrison LH et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin. Infect. Dis. 50(2), 184-191 (2010).
14. Trotter C, Findlow J, Balmer P et al. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin. Vaccine Immunol. 14(7), 863-868 (2007).
15. Meningococcal Reference Unit, Gray SJ, Trotter CL et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol. 55(7), 887-896 (2006). (Pubitemid 43974695)
16. Häyrinen J, Jennings H, Raff HV et al. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J. Infect. Dis. 171(6), 1481-1490 (1995).
17. Novak N, Bieber T. Dendritic cells as regulators of immunity and tolerance. J. Allergy Clin. Immunol. 121(Suppl. 2), S370-S374 (2008). (Pubitemid 351172419)
18. Kolb-Maurer A, Unkmeir A, Kammerer U. Interaction of Neisseria meningitidis with human dendritic cells. Infect. Immun. 69, 6912-6922 (2001). (Pubitemid 32995451)
19. Jones HE, Uronen-Hanson H, Callard RE, Klein N, Dixon GL. The differential response of human dendritic cells to live and killed Neisseria Meningitidis. Cell. Microbiol. 9, 2856-2869 (2007). (Pubitemid 350066570)
20. Hammerschmidt S, Birkholz C, Zahringer U et al. Contribution of genes from the capsule gene complex (cps) to lipooligosaccharide biosynthesis and serum resistance in Neisseria meningitidis. Mol. Microbiol. 11, 885-896 (1994). (Pubitemid 24199656)
21. Vogel U, Weinberger A, Frank R et al. Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis. Infect. Immun. 65, 4022-4029 (1997). (Pubitemid 27422053)
22. Geoffroy MC, Floquet S, Metais A, Nassif X, Pelicic V. Large-scale analysis of the meningococcus genome by gene disruption: resistance to complement-mediated lysis. Genome. Res. 13, 391-398 (2003). (Pubitemid 36395396)
23. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 6(7), e1001027 (2010).
24. Schneider MC, Exely RM, Ram S, Sim RB, Tang CM. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol. 15, 233-240 (2007). (Pubitemid 46671509)
25. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129, 1307-1326 (1969).
26. Jodar L, Cartwright K, Feavers IM. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals 28, 193-197 (2000).
27. Ram S. Binding of fH to meningococci is specific for human fH. Presented at: 15th International Pathogenic Neisseria Conference. Cairns, Queensland, Australia, 10-15 September 2006 2006.
28. Mandrell RE, Azmi FH, Granoff DM. Complement-mediated bactericidal activity of human antibodies to poly a 2?8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. J. Infect. Dis. 172, 1279-1289 (1995).
29. Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40, 257-264 (1983). (Pubitemid 13163064)
30. Santos GF, Deck RR, Donnelly J et al. Importance of complement source in measuring meningococcal bactericidal titers. Clin. Diagn. Lab. Immunol. 8, 616-623 (2001). (Pubitemid 32428891)
31. Jodar L, Cartwright K, Feavers IM. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals 28, 193-197 (2000).
32. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin. Diagn. Lab. Immunol. 8, 616-623 (2001). (Pubitemid 32428891)
33. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69, 1568-1573 (2001). (Pubitemid 32187610)
34. Donnelly J, Medini D, Boccadifuoco G et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl Acad. Sci. USA 107(45), 19490-19495 (2010).
35. Giuliani MM, Biolchi A, Serruto D et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 28(31), 5023-5030 (2010).
36. Wyle FA, Artenstein MS, Brandt BL et al. Immunological response of man to group B meningococcal polysaccharide antigens. J. Infect. Dis. 126, 514-521 (1972).
37. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet 2, 355-357 (1983). (Pubitemid 13028927)
38. Granoff DM. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50(2), S54-S65 (2010).
39. Holst J, Martin D, Arnold R et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27(2), B3-B12 (2009).
40. Fredriksen JH, Rosenqvist E, Wedege E et al. Production, characterization and control of MenB-vaccine Folkehelsa: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14(2), 67-79, discussion 79-80 (1991).
41. Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics 6, 3400-3413 (2006). (Pubitemid 43886156)
42. Williams JN, Skipp PJ, Humphries HE, Christodoulides M, OConnor CD, Heckels JE. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect. Immun. 75, 1364-1372 (2007). (Pubitemid 46385830)
43. Bjune G, Hiby EA, Grnnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093-1096 (1991).
44. Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH 14, 195-207 (1991).
45. de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340, 1074-1078 (1992).
46. Caron F, du Chatelet IP, Leroy JP et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect. Dis. 11(6), 455-463 (2011).
47. Boslego J, Garcia J, Cruz C et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 13, 821-829 (1995).
48. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281(16), 1520-1527 (1999). (Pubitemid 29200936)
49. Rosenqvist E, Hiby EA, Wedege E et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63, 4642-4652 (1995).
50. Wedege E, Kuipers B, Bolstad K et al. Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine. Infect. Immun. 71(7), 3775-3781 (2003). (Pubitemid 36753698)
51. Milagres LG, Gorla MC, Sacchi CT, Rodrigues MM. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. Infect. Immun. 66(10), 4755-4761 (1998). (Pubitemid 28453078)
52. Milagres LG, Gorla MC, Rebelo MC, Barroso DE. Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine. FEMS Immunol. Med. Microbiol. 28(4), 319-327 (2000). (Pubitemid 30417446)
53. Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281(16), 1520-1527 (1999). (Pubitemid 29200936)
54. Wedege E, Hiby EA, Rosenqvist E, Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun. 66(7), 3223-3231 (1998). (Pubitemid 28303120)
55. Rodriguez AP, Dickinson F, Baly A, Martinez R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem. Inst. Oswaldo. Cruz. 94, 433-440 (1999). (Pubitemid 129572516)
56. Oster P, Lennon D, OHallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23(17-18), 2191-2196 (2005). (Pubitemid 40341449)
57. Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J. Infect. Dis. 177(2), 497-500 (1998). (Pubitemid 28063785)
58. Devoy AF, Dyet KH, Martin DR. Stability of PorA during a meningococcal disease epidemic. J. Clin. Microbiol. 43(2), 832-837 (2005). (Pubitemid 40256042)
59. Jódar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 359(9316), 499-508 (2002).
60. Holst J, Feiring B, Fuglesang JE et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 21(7-8), 734-737 (2003). (Pubitemid 36091989)
61. Kelly C, Arnold R, Galloway Y, OHallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am. J. Epidemiol. 166, 817-823 (2007). (Pubitemid 47428901)
62. Galloway Y, Stehr-Green P, McNicholas A, OHallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol. 38, 413-418 (2009).
63. Gorringe AR, Taylor S, Brookes C et al. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin. Vaccine Immunol. 16, 1113-1120 (2009).
64. Bennett JS, Griffiths DT, McCarthy ND et al. Genetic diversity and carriage dynamics of Neisseria lactamica in infants. Infect. Immun. 73, 2424-2432 (2005). (Pubitemid 40470845)
65. Mukhopadhyay TK, Halliwell D, ODwyer C et al. Rapid characterisation of outer membrane proteins in Neisseria lactamica by surface enhanced laser desorption and ionisation - time of flight mass spectroscopy for use in a meningococcal vaccine. Biotechnol. Appl. Biochem. 41, 175-182 (2005). (Pubitemid 40523413)
66. Oliver KJ, Reddin KM, Bracegirdle P et al. Neisseria lactamica protects against experimental meningococcal infection. Infect. Immun. 70, 3621-3626 (2002). (Pubitemid 34666000)
67. Keiser PB, Biggs-Cicatelli S, Moran EE et al. A Phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29, 1413-1420 (2011).
68. Zollinger WD, Donets MA, Schmiel DH et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 28(31), 5057-5067 (2010).
69. Tondella ML, Popovic T, Rosenstein NE et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The active bacterial core surveillance team. J. Clin. Microbiol. 38, 3323-3328 (2000).
70. Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum. Vaccine 3, 290-294 (2007).
71. Holst J, Feiring B, Naess LM et al. The concept of tailor-made, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 23, 2202-2205 (2005). (Pubitemid 40341451)
72. Sandbu S, Feiring B, Oster P et al. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin. Vaccine Immunol. 14, 1062-1069 (2007). (Pubitemid 47518071)
73. Boutriau D, Poolman J, Borrow R et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vaccine Immunol. 14(1), 65-73 (2007).
74. Claassen I, Meylis J, van der Ley P et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14, 1001-1008 (1996). (Pubitemid 26271074)
75. van der Ley P, vander Biezen J, Poolman JT. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13, 401-407 (1995).
76. Rots NY, Kleijne DE. Safety of a nonavalent meningococcal serogroup B vaccine in healthy adult volunteers in a randomised, controlled, single blind study. Presented at: 16th International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
77. de Kleijn ED, de Groot R, Labadie J et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 18, 1456-1466 (2000). (Pubitemid 30017826)
78. Cartwright K, Morris R, Rumke H et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17, 2612-2619 (1999). (Pubitemid 29314456)
79. Peeters CC, Rumke HC, Sundermann LC et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 14, 1009-1015 (1996). (Pubitemid 26271075)
80. Van der Ley P, Poolman JT. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect. Immun. 60, 3156-3161 (1992).
81. Rouppe van der Voort E, Schuller M, Holst J et al. Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys. Vaccine 18, 1334-1343 (2000). (Pubitemid 30017845)
82. van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 25, 2491-2496 (2007). (Pubitemid 46366130)
83. Russell JE, Jolley KA, Feavers IM, Maiden MC, Suker J. PorA variable regions of Neisseria meningitidis. Emerg. Infect. Dis. 10, 674-678 (2004). (Pubitemid 38420299)
84. Sacchi CT, Whitney AM, Popovic T et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J. Infect. Dis. 182, 1169-1176 (2000).
85. Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin. Infect. Dis. 49(4), 597-605 (2009).
86. Harrison LH, Jolley KA, Shutt KA et al. Antigenic shift and increased incidence of meningococcal disease. J. Infect. Dis. 193, 1266-1274 (2006).
87. Tettelin H, Saunders NJ, Heidelberg J et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287, 1809-1815 (2000). (Pubitemid 30143964)
88. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19(17-19), 2688-2691 (2001). (Pubitemid 32234290)
89. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33(4), 530-541 (2010).
90. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA 103(29), 10834-10839 (2006). (Pubitemid 44148381)
91. Comanducci M, Bambini S, Brunelli B et al. NadA, a novel vaccine candidate of Neisseria meningitides. J. Exp. Med. 195(11), 1445-1454 (2002). (Pubitemid 34602821)
92. Serruto D, Spadafina T, Ciucchi L et al. Neisseria meningitidis GNA2132, a heparinbinding protein that induces protective immunity in humans. Proc. Natl Acad. Sci. USA 107(8), 3770-3775 (2010).
93. Miller E, Pollard AJ, Borrow R et al. Safety and immunogenicity of Novartis meningococcal serogroup B vaccine after three doses administered in infancy. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID), Graz, Austria, 13-17 May 2008.
94. Snape M, Dawson T, Oster P et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J. 29(11), 71-79 (2010).
95. Vesikari T et al. Immunogenicity of an investigational multicomponent meningococcal serogroup B vaccine in healthy infants at 2, 4 and 6 months of age. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11-16 September 2010.
96. Esposito S et al. Tolerability of a three-dose schedule of investigational, multicomponent meningococcal serogroup B vaccine and routine infant vaccines in a lot consistency trial. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11-16 September 2010.
97. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroup A, C, W-135 and Y in adult who are at increased risk for occupational exposure to meningococcal isolated. Clin. Vaccine Immunol. 18(3), 483-486 (2011).
98. Brehony C, Wilson DJ, Maiden MC. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 155(12), 4155-4169 (2009).
99. Murphy E, Andrew L, Lee KL et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200(3), 379-389 (2009).
100. Perrett KP, Pollard AJ. Towards and improved serogroup B Neisseria meningitides vaccine. Expert Opin. Biol. Ther. 5, 1611-1625 (2005). (Pubitemid 41771852)
101. Lucidarme J, Comanducci M, Findlow J et al. Characterization of fHbp, NHBA (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J. Clin. Microbiol. 47(11), 3577-3585 (2009).
102. Fletcher LD, Bernfield L, Barniak V et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72, 2088-2100 (2004). (Pubitemid 38419922)
103. Fletcher L, Farley J, Bernfield L et al. Characterization, cloning and expression of different subfamilies of the ORF 2086 gene from Neisseria meningitidis,. Presented at: 13th International Pathogenic Neisseria Conference. National Institute of Public Health, Oslo, Norway, 1-6 September 2002.
104. Zhu D, Zhang Y, Barniak V, Bernfield L, Howell A, Zlotnick G. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect. Immun. 73 (10), 6838-6845 (2005). (Pubitemid 41368851)
105. Nissen MD, Marshall KS, Richmond P et al. A randomized, placebo-controlled, double-blind, Phase I trial of ascending dose of meningococcal group B rLP2086 vaccine. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID). Graz, Austria, 13-17 May 2008.
106. Richmond P, Marshall H, Sheldon E et al. Safety and immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Albert, Canada, 11-16 September 2010.
107. Maiden MC, Ibarz-Pavon AB, Urwin R et al. Impact of meningococcal serogroup C coniugate vaccines on carriage and herd immunity. J. Infect. Dis. 197, 737-743 (2008). (Pubitemid 351364476)
108. OHallahan J, Lennon D, Oster P et al. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal diasease. Vaccine 23, 2197-2201 (2005). (Pubitemid 40341450)
109. Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J. Infect. Dis. 195(10), 1472-1479 (2007). (Pubitemid 46717465)
110. Masignani V, Comanducci M, Giuliani MM et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197, 789-799 (2003). (Pubitemid 36350873)
111. Beernink PT, Granoff DM. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect. Immun. 76(6), 2568-2575 (2008).
112. Welsch JA, Rossi R, Comanducci M, Granoff DM. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol. 172(9), 5606-5615 (2004). (Pubitemid 38542063)
113. Welsch JA, Ram S, Koeberling O, Granoff DM. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197, 1053-1061 (2008). (Pubitemid 351590035)
114. Seib KL, Serruto D, Oriente F et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect. Immun. 77, 292-299 (2009).
115. Harrison LH, Pelton SI, Wilder-Smith A et al. The global meningococcal initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 29, 3363-3371 (2011).
116. Findlow J, Lucidarme J, Comanducci M et al. Characterisation of fhbp, nhba, nadA, porA and sequence type in meningococcal group B case isolates collected in England and Wales in the epidemiological year 2007/2008, and the potential coverage of an investigational group B vaccine. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11-16 September 2010.
117. Cohn AC, Wang X, MacNeil JR et al. Potential impact of serogroup B vaccines: prevalence of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Presented at: IPNC 2010, 17th International Pathogenic Neisseria Conference. Banff, Canada, 11-16 September 2010.
118. Holst J, Bambini S, Muzzi A et al. Sequence variation and degree of expression for five genome-derived vaccine antigens included in the MenB Novartis investigational vaccine. Presented at: IPNC 2010, 17th International Pathogenic Neisseria Conference. Banff, Canada, 11-16 September 2010.
119. Muzzi A, Bambini S, Comandi S et al. Factor H binding protein (fHbp) variability within the ST-41 and ST-44 sub-complexes of cc41/44. Presented at: IPNC 2010, 17th International Pathogenic Neisseria Conference. Banff, Canada, 11-16 September 2010.
120. Findlow J, Borrow R, Snape MD et al. Multicenter, open-label, randomized Phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51(10), 1127-1137 (2010).
121. Taha MK, Alonso JM. Meningococcal vaccines: to eradicate the disease, not the bacterium. Hum. Vaccines 3(4), 149-152 (2007).
122. Horton RE, Stuart J, Christensen H et al. Influence of age and carriage status on salivary IgA to Neisseria meningitidis. Epidemiol. Infect. 133, 883-889 (2005). (Pubitemid 41478974)
123. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 10, 853-861 (2010).
124. Davenport V, Groves E, Horton RE et al. Mucosal immunity in healthy adults after parenteral vaccination with outermembrane vesicles from Neisseria meningitidis serogroup B. J. Infect. Dis. 198, 731-740 (2008).
125. WHO. Meningococcal meningitis www.who.int/mediacentre/factsheets/ fs141/en
126. EU-IBIS - European Union invasive bacterial infections surveillance network. Invasive Neisseria meningitidis in Europe 2006 Health Protection Agency, London (2006) www.hpa-bioinformatics.org.uk/euibis/ documents/2006- meningo.pdf